

University of Groningen

Assessing intestinal permeability in Crohn's disease patients using orally administered ⁵²Cr-EDTA

von Martels, Julius Z. H.; Bourgonje, Arno R.; Harmsen, Hermie J. M.; Faber, Klaas Nico; Dijkstra, Gerard

Published in:
 PLoS ONE

DOI:
 [10.1371/journal.pone.0211973](https://doi.org/10.1371/journal.pone.0211973)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

von Martels, J. Z. H., Bourgonje, A. R., Harmsen, H. J. M., Faber, K. N., & Dijkstra, G. (2019). Assessing intestinal permeability in Crohn's disease patients using orally administered ⁵²Cr-EDTA. *PLoS ONE*, 14(2), [e0211973]. <https://doi.org/10.1371/journal.pone.0211973>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

RESEARCH ARTICLE

Assessing intestinal permeability in Crohn's disease patients using orally administered ^{52}Cr -EDTA

Julius Z. H. von Martels^{1☯*}, Arno R. Bourgonje^{1☯}, Hermie J. M. Harmsen², Klaas Nico Faber¹, Gerard Dijkstra¹

1 Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, **2** Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

☯ These authors contributed equally to this work.

* j.z.h.von.martels@umcg.nl



Abstract

OPEN ACCESS

Citation: von Martels JZH, Bourgonje AR, Harmsen HJM, Faber KN, Dijkstra G (2019) Assessing intestinal permeability in Crohn's disease patients using orally administered ^{52}Cr -EDTA. PLoS ONE 14 (2): e0211973. <https://doi.org/10.1371/journal.pone.0211973>

Editor: Jan S. Suchodolski, Texas A&M University College Station, UNITED STATES

Received: October 11, 2018

Accepted: January 24, 2019

Published: February 7, 2019

Copyright: © 2019 von Martels et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are contained within the paper.

Funding: The research position of drs. J.Z.H. von Martels is financed by the Top Institute of Food and Nutrition (TIFN) in Wageningen and the Center for Development & Innovation of the University Medical Center Groningen. The research position of Arno R. Bourgonje is supported by a JSM MD-PhD trajectory grant (grant number: 17-57) from the Junior Scientific Masterclass of the University of Groningen, the Netherlands. The funders had no

Background

Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively ^{51}Cr -labeled ethylenediaminetetraacetic acid (^{51}Cr -EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administered ^{52}Cr -EDTA as non-radioactive alternative to assess intestinal permeability in CD and analyzed the association with disease activity, disease location and gut microbial dysbiosis.

Materials and methods

60 CD patients with low ($n = 25$) and increased ($n = 35$) fecal calprotectin levels (cut-off: 100 $\mu\text{g/g}$ feces) ingested 20 mL ^{52}Cr -EDTA (20 mmol/L) solution whereafter 24-h urine was collected. Urinary ^{52}Cr -EDTA concentrations were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Fecal *Enterobacteriaceae* and *Faecalibacterium prausnitzii* were quantified using FISH. Correlations between urinary ^{52}Cr -EDTA excretion and other parameters were established using nonparametric Spearman's correlation coefficients (ρ).

Results

CD patients with increased fecal calprotectin levels ($> 100 \mu\text{g/g}$) demonstrated an elevated urinary ^{52}Cr -EDTA/creatinine ratio (772 vs. 636 $\mu\text{mol/mol}$, $P = 0.132$). Patients with primarily colonic disease showed the highest ^{52}Cr -EDTA excretion. Importantly, a positive correlation was observed for the urinary ^{52}Cr -EDTA/creatinine ratio and fecal calprotectin levels ($\rho = 0.325$, $P < 0.05$). Finally, urinary ^{52}Cr -EDTA/creatinine ratio negatively correlated with the relative abundance of *Faecalibacterium prausnitzii* ($\rho = -0.221$, $P = 0.092$), while positively correlating with *Enterobacteriaceae* ($\rho = 0.202$, $P = 0.126$).

role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Conclusions

Orally administered and renal excreted ⁵²Cr-EDTA may be used to assess intestinal permeability in CD and correlates with fecal calprotectin levels and bacterial species relevant to CD. This test may improve non-invasive detection of disease exacerbations and help monitor disease activity.

Introduction

In Crohn's disease (CD), a disturbed balance between the gut mucosal immune system and intestinal microbiota is intimately associated with diminished functioning of the intestinal barrier. This barrier is instrumental in the protection against adhesion and infiltration of intraluminal antigens into the underlying lamina propria, thereby maintaining a healthy gut. An important functional and measurable feature of the gastro-intestinal barrier constitutes intestinal permeability, which is influenced by both the gut microbiota and mucosal immunity. [1] Intestinal microbiota play a pivotal role in preserving gut epithelial barrier integrity. A strong link exists between microbial dysbiosis and intestinal permeability. [2] Intestinal dysbiosis in CD is characterized by increased numbers of (potentially) pathogenic bacteria, such as several members of the *Enterobacteriaceae*, and a decreased abundance of commensal bacteria, such as *Faecalibacterium prausnitzii*. Decreased abundance of *Faecalibacterium prausnitzii* is consistently observed in CD and is associated with increased inflammation and presumably disrupted intestinal barrier integrity. [3,4] Similarly, *Enterobacteriaceae*, e.g. adherent-invasive *Escherichia coli* (AIEC), are known to possess multiple pathogenic mechanisms that can lead to loss of intestinal barrier function. [5] These typical shifts of many bacterial species that are characteristic for CD dysbiosis are putatively related to either gain or loss of intestinal epithelial barrier function (such as *Faecalibacterium prausnitzii* and *Enterobacteriaceae* (e.g. *Escherichia coli*), respectively). [6,7]

An impaired intestinal permeability has been associated with many gastro-intestinal (GI) and non-GI diseases. [1] In inflammatory bowel disease (IBD) research, there has been much scientific interest in unraveling the complex association between a comprised gut wall integrity and mucosal inflammation. Until now, however, it is not fully understood whether a defective mucosal barrier in IBD promotes intestinal inflammation or that impaired barrier function is secondary to the inflammatory process. [8,9] Nonetheless, the link between an increased intestinal permeability and increased inflammatory activity is well-established. [10] There is also increasing evidence that an increased intestinal permeability to macromolecules precedes the onset of IBD and/or is a sign of subclinical disease activity. It may therefore be used as an early predictor of clinical relapses in IBD patients. [11–14] This is illustrated by the fact that a subset of clinically healthy first-degree relatives of Crohn's disease patients are genetically predisposed to an increased intestinal permeability as compared to healthy controls. [15,16]

Despite this strong association, inflammatory disease activity has hitherto been monitored inconsistently in clinical practice. Since a poor association exists between clinically active disease and observed endoscopic disease activity, non-invasive biomarkers have increasingly been studied to predict active intestinal inflammation in CD. [17] For instance, biochemical disease parameters such as the fecal calprotectin (FC) level and serum C-reactive protein (CRP) are being widely utilized, since these markers correlate significantly with endoscopically active disease. [18–20] In this study, we use fecal calprotectin levels as an accurate indirect measure of inflammatory disease activity. [21,22]

Currently, orally administered tracers for intestinal permeability play no significant role in monitoring disease exacerbations in CD, but may aid in the diagnostic accuracy of the

currently available panel of non-invasive disease biomarkers and help predict CD disease course. [19,23,24] The clinical utility and validity of these non-invasive tests for intestinal permeability are still not fully established. [1] An optimal intestinal permeability test should have a number of properties. The test or marker is preferably sensitive, accurate, reproducible and safe in order to assist in diagnosis and monitoring of disease flares. In addition, an *in vivo* marker should be stable and inert, avoiding metabolism and degradation. [1,14]

Numerous studies have evaluated intestinal permeability using radioactively ^{51}Cr -labeled ethylenediaminetetraacetic acid (^{51}Cr -EDTA). [11,12,25–33] However, these previously published studies have been unable to establish a consistent correlation between ^{51}Cr -EDTA-measured gut permeability and inflammatory disease activity, likely related to relatively small and heterogeneous IBD study cohorts. Apart from this, most of these studies used the less preferred radioactively ^{51}Cr -labeled EDTA, followed by urinary analysis of gamma radiation. Conjointly, its individual performance in clinical practice remains mostly unfeasible due to complex and impractical detection methods. [1,29] A similar substance has recently been developed to evaluate intestinal permeability, in which the non-radioactive ^{52}Cr isotope has been incorporated into ^{52}Cr -EDTA. This allows us to measure urinary ^{52}Cr content in a safe, inexpensive and precisely validated manner using the highly sensitive method of Inductively Coupled Plasma Mass Spectrometry (ICP-MS). In contrast to radioactively labeled ^{51}Cr -EDTA, only few studies have evaluated the performance of ^{52}Cr -EDTA as a tracer for intestinal permeability. [34–36] ^{52}Cr -EDTA has proven to be a sensitive marker for human intestinal permeability, both in health and disease. [35–39] Cr and EDTA form a stable and inert complex with one of the highest affinity of known metals, without any physicochemical interactions that might be expected to occur. [40,41] However, putative correlations between ^{52}Cr -EDTA-measured intestinal permeability and CD-specific disease parameters have not yet been established.

The aim of this study is to evaluate intestinal permeability through measuring 24-h urinary excretion of orally administered ^{52}Cr -EDTA in Crohn's disease and its association with inflammatory disease activity, disease localization and two key bacterial marker strains of CD dysbiosis (*Faecalibacterium prausnitzii* and *Enterobacteriaceae*).

Materials and methods

Study population

Patients aged 18–65 years were recruited from March 2016 until April 2017 at the outpatient IBD clinic of the University Medical Center Groningen (UMCG), Groningen, The Netherlands. All patients were diagnosed with Crohn's disease (CD), according to clinical, endoscopic and histopathological features. All patients were Caucasians and lived in the Northern part of the Netherlands. Patients were divided into two groups based on fecal calprotectin levels as a measure of inflammatory disease activity (using 100 μg calprotectin / gram feces as our currently used cut-off value for defining low and increased inflammatory disease activity). Standard demographic characteristics, including age, sex, body-mass index (BMI) and smoking history, were recorded, as well as clinical parameters specific for CD, such as the Harvey-Bradshaw index (HBI), Montreal disease classification (including Age at diagnosis (A), Location of disease (L) and the Behavior (B) of the disease) and current maintenance therapy. Disease location was recorded from the most recently performed endoscopic evaluation, which was completed within 12 months of intestinal permeability testing. CD patients who were treated with antibiotics 3 months prior to screening were not eligible for this study (to rule out an effect on the microbiota composition). Furthermore, CD patients with severe disease activity, as reflected by a HBI score > 12 , or patients with an indication for remission-induction therapy, were also excluded from this study. Routine laboratory examinations were performed,

including hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), leukocyte count, thrombocyte count and creatinine levels. Fecal calprotectin levels were quantified by enzyme-linked immunosorbent assays (ELISA) (BÜHLMANN Laboratories AG, Switzerland) as a routine measurement in the UMCG. Samples were obtained after patients gave written informed consent. This study has been approved by the Institutional Medical Ethical Review Board (in Dutch: Medisch Ethische Toetsingcommissie, METc) of the University Medical Center Groningen (UMC Groningen) (IRB no. 2014/291) and is in accordance with the principles of the Declaration of Helsinki (2013).

⁵²Cr-EDTA solution

The chromium-EDTA oral test solution consists of the active ingredients chromium(III)chloride ($\text{CrCl}_3 \cdot 6\text{H}_2\text{O}$) and disodium edetate ($\text{C}_{10}\text{H}_{14}\text{N}_2\text{Na}_2\text{O}_8 \cdot 2\text{H}_2\text{O}$), 70% sorbitol liquid crystalline and raspberry essence as sweeteners, 0.1 M NaOH for pH adjustment to reach a final pH between 4.5–5.5, methylparahydroxybenzoate as preservative and purified water (according to Ph. Eur. requirements) as solvent. The solution contained in total 400 μmol of ⁵²Cr-EDTA (20 mmol/L). Patients were instructed to drink the ⁵²Cr-EDTA solution (20 mL) together with a glass of water after an overnight fast. Subsequently, patients were asked to fast for an additional 2 hours. Urine was collected for 24 hours from the moment of ingestion of the ⁵²Cr-EDTA test solution. Patients were also instructed to refrain from the intake of alcoholic beverages or non-steroidal anti-inflammatory drugs (NSAID's) two days prior to taking the ⁵²Cr-EDTA solution and during the 24-h urine collection period. Full details on the preparation of the ⁵²Cr-EDTA solution were described previously. [42]

Analytical procedure

Urinary content of ⁵²Cr was quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS), which is a highly sensitive analytical method for measuring various metals, including chromium isotopes (Nexion 300X, Perkin Elmer, Medlon BV Enschede, The Netherlands). [43] First, 24-h urine samples were 30-fold diluted with 0.5% HNO_3 and 0.01% Triton X-100, after which ¹⁰³Rh was added as internal standard (IS). Subsequently, the sample analyte was nebulized in a cyclonic spray chamber, atomized at extremely high temperature (ranging from 6,000–8,000°C) and ionized using argon (Ar) plasma. Using a vacuum of ~ 20 mL/min, the resulting ions were deflected into a quadrupole in which ions are separated based on their electrical charge and mass, under the influence of an alternating electrical current. Finally, chromium ions were detected via an electron multiplier. Urinary chromium (⁵²Cr) was measured while applying the kinetic energy discrimination (KED) mode, ensuring a general reduction of polyatomic isobaric interferences (such as that of ⁴⁰Ar¹²C). Final urinary ⁵²Cr concentrations (nmol/L) were divided by urinary creatinine concentrations (mmol/L) as correction for hydration. Urinary creatinine levels were quantified by an enzymatic detection method following supplier's instructions (Roche Diagnostics, Roche Modular P Analyzer, Mannheim, Germany).

Quantification of fecal bacteria using fluorescent in-situ hybridization (FISH)

The quantification of *Faecalibacterium prausnitzii* and *Enterobacteriaceae* was performed as previously described, with some minor modifications. [44] Patients were asked to provide fecal samples at the time of the 24-h urine collection. Samples were mixed with 4.5 mL filtered phosphate-buffered saline (PBS) and centrifuged at 700 g for 2–3 min. The resulting supernatant was 4-fold diluted with freshly-prepared 4% paraformaldehyde solution and stored

Table 1. Bacterial probes used in the fluorescent in-situ hybridization (FISH).

Target	Probe	Label	Sequence 3' > 5'
Total bacteria	Eub338	Rhodamine	TGAGGATGCCCTCCGTCG
<i>F. prausnitzii</i>	Fprau645	FITC	CAAAAAGAACTCATCAGTCTCC
<i>Enterobacteriaceae</i>	Ec1531	CY3	ACTACTGCTCCGTGATGCCAC

<https://doi.org/10.1371/journal.pone.0211973.t001>

overnight at 4°C. Before counting, samples were coded and randomized by an independent investigator. Serial dilutions were prepared to allow visual counting of total bacteria, *Enterobacteriaceae* and *F. prausnitzii*. Each dilution was spread over gelatin-coated glass slides and dried at room temperature. After addition of the appropriate bacterial probes (see Table 1), Eub338 (Rhodamine) for the total bacteria, Fprau645 (FITC) for *F. prausnitzii* and Ec1531 (CY3) for *Enterobacteriaceae*, slides were hybridized overnight at 50°C. [45–47] In each glass slide well, 25 fields were manually quantified using fluorescent microscopes (Leica 2 or Olympus BH20 at 100X magnification). Bacteria were quantified using two different filters, FITC or CY3, based on the probe colour. Based on the absolute bacterial counts, the relative percentage of each bacterial group was calculated.

Statistics

Characteristics of the study population were shown as proportions (%), means \pm standard deviations (SD) or medians with interquartile range (IQR), as appropriate. Normality testing was performed using Kolmogorov-Smirnov tests. Distributions of urinary ⁵²Cr-EDTA/Cr excretion were presented as median \pm interquartile ranges (IQR) and presented in boxplots (10th–90th percentiles) grouped by inflammatory disease activity, as determined by the fecal calprotectin level (using 100 μ g/g feces as cut-off value). Differences between groups were tested using the independent sample *t*-test or Mann-Whitney U-test, as appropriate. Partial correlations between urinary ⁵²Cr-EDTA/creatinine ratio and other parameters were performed using the nonparametric Spearman's correlation coefficient (ρ). Associations between correlated parameters were visualized in scatter plots with smoothed curves. Smoothing was empirically applied by nonlinear regression using 2nd order polynomial functions with 1/*y*² weighting. Statistical analyses were performed using SPSS Statistics 23.0 for Windows. *P*-values \leq 0.05 were considered as statistically significant.

Results

Study cohort characteristics are shown in Table 2. Crohn's disease (CD) patients with low fecal calprotectin levels (*n* = 25) had a mean age of 44.1 \pm 13.3 years and consisted of 8 males (32.0%) and 17 females (68.0%), while patients with increased fecal calprotectin levels (*n* = 35) had a mean age of 40.5 \pm 12.2 years and consisted of 10 males (28.6%) and 25 females (71.4%). Patients with increased levels of fecal calprotectin showed significantly elevated white blood cell counts (WBC) (*P* < 0.05) and erythrocyte sedimentation rates (ESR) (*P* < 0.05). CD patients with an increased level of fecal calprotectin had a significantly lower alcohol consumption as compared to CD patients with low fecal calprotectin levels (*P* < 0.01). No significant differences were observed for any other cohort characteristic. Also, clinical disease activity, as measured by the Harvey-Bradshaw Index (HBI), was not significantly different between patients with either low or increased fecal calprotectin levels. In the total study cohort, median HBI score was 3 (IQR: 1–5), indicating that the majority of patients were in clinical remission at the time of inclusion.

Urinary ⁵²Cr-EDTA/creatinine excretion proportionally increases with fecal calprotectin levels

Distributions of the 24-h urinary ⁵²Cr-EDTA/creatinine ratio among both groups are shown in Fig 1A. CD patients with increased fecal calprotectin levels showed a trend of elevated

Table 2. Characteristics of Crohn's disease patients (*n* = 60) with fecal calprotectin levels indicative of remissive disease (< 100 µg/g) and increased disease activity (> 100 µg/g). Data are presented as numbers (*n* (%)), mean ± SD or median [IQR][†].

Characteristics	FC < 100 µg/g (<i>n</i> = 25)	FC > 100 µg/g (<i>n</i> = 35)	<i>P</i> -value
Age (years)	44.1 ± 13.3	40.5 ± 12.2	0.431
Male gender	8 (32.0)	10 (28.6)	0.783
BMI (kg/m ²)	25.6 ± 4.5	24.3 ± 5.4	0.233
Active smoking	5 (20.0)	7 (20.0)	1.000
Alcohol consumption (g/day)	3.6 [0.9;11.1]	0.8 [0.1;2.6]	0.009**
Ileocecal resection	11 (44.0)	13 (37.1)	0.606
HBI			0.313
Remission (< 5)	17 (68.0)	25 (71.4)	
Mild disease (5–7)	6 (24.0)	4 (11.4)	
Moderate disease (8–12)	2 (8.0)	6 (17.1)	
Maintenance medication			0.936
None	7 (28.0)	8 (22.9)	
Thiopurines	5 (20.0)	9 (25.7)	
Mesalamine	3 (12.0)	6 (17.1)	
TNF-antagonists	7 (28.0)	9 (25.7)	
Combination therapy	3 (12.0)	3 (8.6)	
Montreal, Age at diagnosis			0.397
A1 (< 17 yr)	4 (16.0)	5 (14.3)	
A2 (17–40 yr)	15 (60.0)	26 (74.3)	
A3 (> 40 yr)	6 (24.0)	4 (11.4)	
Montreal, Localization			0.476
L1 (ileal)	12 (48.0)	12 (34.3)	
L2 (colonic)	4 (16.0)	5 (14.3)	
L3 (ileocolonic)	9 (36.0)	18 (51.4)	
Montreal, Behavior			0.642
B1 (non-stricturing, non-penetrating)	11 (44.0)	18 (51.4)	
B2 (stricturing)	9 (36.0)	13 (37.1)	
B3 (penetrating)	5 (20.0)	4 (11.4)	
Laboratory values			
CRP (mg/L)	0.9 [0.5;3.3]	2.6 [0.9;5.0]	0.052
ESR (mm/h)	8.0 [3.0;18.0]	13.0 [9.0;27.0]	0.028*
WBC (x10 ⁹ /l)	6.4 ± 1.6	7.8 ± 2.2	0.013*
FC (µg/g)	45 [40;67]	360 [175;760]	0.000***
Thrombocytes (x10 ⁹ /l)	288 ± 82	287 ± 67	0.776
Creatinine (µmol/l)	75 ± 15	71 ± 11	0.245

[†]FC, fecal calprotectin; BMI, body mass index; HBI, Harvey Bradshaw Index; TNF, tumor necrosis factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count. Differences between groups were tested using the independent sample *t*-test or Mann-Whitney U-test for continuous variables and the Fisher's exact test for discontinuous variables, as appropriate. Two-sided *P*-values < 0.05 were considered as statistically significant.

**P* < 0.05

***P* < 0.01

****P* < 0.001.

<https://doi.org/10.1371/journal.pone.0211973.t002>




Fig 1. The relationship between levels of urinary 24-h ^{52}Cr -EDTA/creatinine excretion and fecal calprotectin. (A) Distribution of urinary ^{52}Cr -EDTA/creatinine excretion in patients with low (blue, < 100 µg/g) and increased (red, > 100 µg/g) fecal calprotectin levels, shown in boxplots. (B) Urinary ^{52}Cr -EDTA/creatinine excretion significantly correlates with fecal calprotectin levels ($\rho = 0.325$, $P < 0.05$), as represented by the red smoothed curve.

<https://doi.org/10.1371/journal.pone.0211973.g001>

urine-excreted ^{52}Cr -EDTA/creatinine (771.8 µmol/mol (IQR: 472.4–1005.9) vs. 636.4 µmol/mol (IQR: 365.0–843.4), $P = 0.132$). Importantly, we observed a significant correlation between

Disease localization




Fig 2. Urinary 24-h excretion of ^{52}Cr -EDTA/creatinine for different subgroups of CD patients according to the Montreal classification of disease localization. No significant differences were observed between any groups ($P > 0.05$).

<https://doi.org/10.1371/journal.pone.0211973.g002>




Fig 3. Correlations of 24-h urinary excretion of ⁵²Cr-EDTA/creatinine with the relative abundances of key bacterial species in the diseased gut, as represented by the red smoothed lines. (A) A negative correlation ($\rho = -0.221$, $P = 0.092$) is observed between the relative abundance (%) of *F. prausnitzii* and urinary ⁵²Cr-EDTA/creatinine excretion, though this was not statistically significant. (B) A positive correlation ($\rho = 0.202$, $P = 0.126$) is observed between the relative abundance (%) of *Enterobacteriaceae* and urinary ⁵²Cr-EDTA/creatinine excretion, though this correlation was also not statistically significant.

<https://doi.org/10.1371/journal.pone.0211973.g003>

urinary ⁵²Cr-EDTA/creatinine excretion and fecal calprotectin levels ($\rho = 0.325$, $P < 0.05$, Fig 1B), while controlling for gender, disease localization, ileocecal resection status and alcohol consumption.

Urinary ⁵²Cr-EDTA/creatinine excretion is highest in CD patients with solely colonic disease

No significant differences in 24-h urinary excretion of ⁵²Cr-EDTA/creatinine were observed for subgroups of CD patients with different disease localization according to the Montreal classification ($P = 0.270$, Fig 2). Still, CD patients with solely colonic disease showed the highest median urinary ⁵²Cr-EDTA/creatinine excretion (791 μmol/mol (IQR: 632–1088), $n = 9$), whereas median excretion in patients with ileal involvement was lower (ileal disease: 472 μmol/mol (IQR: 312–821), $n = 24$; ileocolonic disease: 676 μmol/mol (IQR: 417–1006), $n = 27$, $P = 0.093$).

Correlation analysis between urinary ⁵²Cr-EDTA/creatinine excretion and relative abundances of CD-associated bacterial species

The absolute and relative abundance of two CD-associated bacteria, *F. prausnitzii* and *Enterobacteriaceae*, was quantified by FISH analysis in fecal samples of all patients (see S1 Fig for representative fluorescence microscopy images and S1 Table for quantifications). Among CD patients with below-median and above-median ⁵²Cr-EDTA/creatinine excretion, there were no significant differences detected in relative abundances (%) of *F. prausnitzii* and *Enterobacteriaceae*. Interestingly, we observed a borderline non-significant negative correlation between 24-h urinary ⁵²Cr-EDTA/creatinine excretion and relative numbers of *F. prausnitzii* ($\rho = -0.221$, $P = 0.092$, Fig 3A). In contrast, a moderately positive correlation, though non-significant, was found between 24-h urinary ⁵²Cr-EDTA/creatinine excretion and relative numbers of *Enterobacteriaceae* species ($\rho = 0.202$, $P = 0.126$, Fig 3B).

Discussion

In this study, we show that increased urinary excretion of orally administered ⁵²Cr-EDTA significantly correlates with elevated levels of fecal calprotectin in CD patients. Furthermore, CD patients with solely colonic disease activity show elevated ⁵²Cr-EDTA/creatinine urinary excretion as opposed to CD patients having only an affected ileum. In addition, we observed an interesting trend of a negative association between ⁵²Cr-EDTA-measured intestinal permeability and relative numbers of *F. prausnitzii*, whereas a trend of a positive association was observed between *Enterobacteriaceae* counts and urinary ⁵²Cr-EDTA excretion. These correlations, though they lacked statistical significance, may suggest the possibility of a relationship between intestinal permeability and intestinal dysbiosis. Overall, our findings suggest that the measurement of urinary ⁵²Cr-EDTA excretion might serve as novel approach for determining compromised intestinal permeability, as is characteristic for severe CD.

Chromium-EDTA has been widely used as marker for intestinal permeability, due to its high sensitivity and the stability of the Cr-EDTA complex. [35] However, most studies used the radioactive form ⁵¹Cr-EDTA that may have adverse effects due to radiation exposure. Here, we assessed the non-radioactive and inert ⁵²Cr-EDTA to evaluate intestinal permeability in CD, in combination with quantifying urinary ⁵²Cr by highly-sensitive ICP-MS. This method is particularly useful in detecting metal isotopes at very low concentrations in a safe, inexpensive and rigorously validated manner (Nexion 300X, Perkin Elmer, Medlon BV Enschede, The Netherlands). The currently applied ICP-MS method appeared to be highly sensitive in detecting ⁵²Cr, with an internally determined lower limit of quantification (LLOQ) of 9.8 nmol/L. The average concentration of endogenous chrome in individuals in human blood and urine lies in the range of 0.1–0.5 µg/L (1.9–9.6 nmol/L), which falls below the LLOQ of ICP-MS and is thus negligibly small. For instance, the lowest individual value measured in our study cohort was 1352 nmol/L. [48]

This study assessed the ⁵²Cr-EDTA intestinal permeability test in a relatively large study cohort of CD patients. Interestingly, the majority of these patients (70%) were in clinical remission according to the HBI, but still show a large variation in ⁵²Cr-EDTA-measured intestinal permeability. Our study cohort is larger and less heterogeneous than all previous performed studies that have evaluated the potential application of Chromium-EDTA-measured intestinal permeability in IBD. [11,12,25–33] Patient participation within our study was high, due to the non-invasive and non-radioactive nature of this test. However, careful test monitoring was required since several factors could affect urinary excretion levels of ⁵²Cr-EDTA, such as adherence to the experimental protocol and the duration of urine collection. [49] Also, in the present study cohort, no endoscopic disease activity data were available, which are preferentially used as representative of inflammatory disease activity in CD. Alternatively, we used the fecal calprotectin level as surrogate marker for CD disease activity. [19,20,50–52] Here, fecal calprotectin levels were directly related to ⁵²Cr-EDTA-measured intestinal permeability, which has previously not been established.

Few studies specifically focused on the association between increased ⁵¹Cr-EDTA-measured intestinal permeability and inflammatory disease activity. [26,32,53] Hitherto, Berstad *et al.* found a significant correlation between 5-h urinary ⁵¹Cr-EDTA excretion and calprotectin levels in gut lavage fluid of IBD patients. [53] Another study observed an association between increased ⁵¹Cr-EDTA-measured intestinal permeability and serum levels of acute-phase reactants and ¹¹¹In-labeled leukocyte scans. [32] In UC, a significant correlation between ⁵¹Cr-EDTA-measured intestinal permeability and endoscopic disease activity was demonstrated. [26] In CD, it has been shown that anti-TNF treatment attenuates mucosal inflammation and also improves intestinal integrity measured by orally administered ⁵¹Cr-

EDTA. [54] Although the relationship between disease activity and Cr-EDTA-measured intestinal permeability seems to be well-established, studies show weak comparability because of various study designs, different intestinal permeability tracers and varying time intervals. Furthermore, it is difficult to clearly demonstrate this relationship since many factors are known to affect intestinal permeability, such as disease localization, surgical history, alcohol consumption, medication use, commensal bacteria and many dietary components. [55] As a consequence, the extent of this relationship remains inconclusive. In addition, all the previously mentioned studies are remarkably contradictory as to the primary intestinal location and degree of increased ⁵¹Cr-EDTA bowel passage. [25–29] In our study cohort, CD patients with exclusively colonic disease activity showed a higher median urinary ⁵²Cr-EDTA/creatinine excretion as compared to patients with ileal involvement, though non-significantly. Similarly, we could not demonstrate any statistically significant differences in intestinal permeability between three different subgroups of disease localization (i.e. ileal, colonic or ileocolonic disease).

Until now, it remains unclear whether increased intestinal permeability is secondary to sub-clinical mucosal inflammation in CD or vice versa. [56,57] Accumulating evidence suggests that increased intestinal permeability may be the consequence of a genetically pre-existing epithelial barrier abnormality in certain individuals that predisposes them to the onset of intestinal inflammation. [58] Various studies have shown that a subset of clinically healthy first-degree relatives of Crohn's disease patients show increased intestinal permeability as compared to healthy controls. [15,16] Moreover, it has been hypothesized that impaired intestinal permeability may already be apparent long before any mucosal inflammation is present and could be predictive of clinical relapse. In addition, another study demonstrated that in first-degree relatives of CD patients subclinical intestinal inflammation is present, reflected by an increased fecal calprotectin level. [59] In our study, we found a significant correlation between intestinal inflammatory disease activity (as represented by fecal calprotectin levels) and intestinal permeability (as measured by urinary ⁵²Cr EDTA excretion). Overall, this indicates that ⁵²Cr-EDTA-measured intestinal permeability might be particularly useful in defining the first stages of development of Crohn's disease in a subgroup of unaffected, genetically susceptible individuals.

CD patients typically demonstrate a decreased gut microbiota diversity as compared to healthy individuals. [60] An important observation in CD is the reduction in the commensal anaerobic, butyrate-producing bacterium *F. prausnitzii*, as well as an increased number of *Enterobacteriaceae* (e.g. *Escherichia coli*). [3,6,61] In the present study, we observed a negative non-significant relationship between ⁵²Cr-EDTA-measured intestinal permeability and the relative abundance of *F. prausnitzii*, while a positive non-significant relationship was observed between the relative abundance of *Enterobacteriaceae* and urinary ⁵²Cr-EDTA excretion in CD patients. These interesting associations (though moderate and non-significant) support the existence of a link between the gut microbiota composition and the integrity of the intestinal barrier. Future studies are needed to further elucidate this relationship, for example through *in vitro* modeling of host-microbe interactions using bacteria-gut epithelial co-culture systems. [6] In this way, the influence of specific bacterial species on epithelial markers for intestinal permeability may give more fundamental insight into this complex association.

In conclusion, we show that a moderate positive correlation exists between ⁵²Cr-EDTA-measured intestinal permeability and fecal calprotectin levels. In addition, we demonstrate interesting, though non-significant correlations between intestinal permeability and two key gut bacterial species, suggesting the possibility of a relationship between dysbiosis and permeability. Future studies should primarily focus on the utility of orally administered ⁵²Cr-EDTA as measure of intestinal permeability in relation to endoscopic disease activity and its potential role as predictor of CD disease exacerbations.

Supporting information

S1 Fig. Fluorescence in situ hybridization (FISH) experiments quantify the absolute and relative amounts of selected bacteria in fecal samples. Paraformaldehyde-fixed fecal samples were hybridized with specific fluorescent oligonucleotide probes and visualized with an Olympus BH2 epifluorescence microscope. Images are shown as examples and are taken from random samples not related to each other. (A) Epifluorescent images of a hybridization with a Rhodamine-labeled Eub338 probe specific for almost all bacteria at a 1600 x dilution of a fecal patient sample. (B) Hybridization with a FITC-labeled *Faecalibacterium prausnitzii*-specific probe Fprau645 of a 160 x diluted fecal sample. (C) Hybridization with the Fprau645 probe at 40 x dilution of the fecal sample. (D) Hybridization with the CY3-labeled *Enterobacteriaceae*-specific probe Ec1531 at a 40x dilution of the fecal sample. Bar, 20 μ m. (TIF)

S1 Table. Median numbers of *F. prausnitzii* and *Enterobacteriaceae* per gram of feces and their relative abundances (%) to total microbiota (Eub338). Data are shown for the total study cohort ($n = 60$), and for subgroups of CD patients with below- and above-median urinary ⁵²Cr-EDTA/creatinine excretion. Data are presented as median (IQR). (DOCX)

Acknowledgments

We would like to thank Ronald Maatman and research technician Harry Wanschers from 'Medlon Medische Diagnostiek' in Enschede. We also want to thank Hassan Alkhalifah for contributing to the FISH analysis.

Author Contributions

Conceptualization: Julius Z. H. von Martels, Arno R. Bourgonje, Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

Data curation: Julius Z. H. von Martels, Arno R. Bourgonje, Gerard Dijkstra.

Formal analysis: Julius Z. H. von Martels, Arno R. Bourgonje.

Funding acquisition: Julius Z. H. von Martels, Arno R. Bourgonje, Gerard Dijkstra.

Investigation: Julius Z. H. von Martels, Arno R. Bourgonje, Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

Methodology: Julius Z. H. von Martels, Arno R. Bourgonje, Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

Project administration: Julius Z. H. von Martels, Arno R. Bourgonje, Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

Resources: Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

Software: Julius Z. H. von Martels, Arno R. Bourgonje.

Supervision: Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

Validation: Arno R. Bourgonje, Gerard Dijkstra.

Visualization: Arno R. Bourgonje.

Writing – original draft: Julius Z. H. von Martels, Arno R. Bourgonje.

Writing – review & editing: Julius Z. H. von Martels, Arno R. Bourgonje, Hermie J. M. Harmsen, Klaas Nico Faber, Gerard Dijkstra.

References

1. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterology*. 2014; 14: 189. <https://doi.org/10.1186/s12876-014-0189-7> PMID: 25407511
2. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. *Inflamm Bowel Dis*. 2011; 17(1): 362–381. <https://doi.org/10.1002/ibd.21403> PMID: 20725949
3. Cao Y, Shen J, Ran ZH. Association between *Faecalibacterium prausnitzii* Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. *Gastroenterol Res Pract*. 2014; 2014: 872725. <https://doi.org/10.1155/2014/872725> PMID: 24799893
4. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008; 105: 16731–16736. <https://doi.org/10.1073/pnas.0804812105> PMID: 18936492
5. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, et al. Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Gut*. 2018; 67(3): 574–587. <https://doi.org/10.1136/gutjnl-2017-314903> PMID: 29141957
6. von Martels JZH, Sadaghian Sadabad M, Bourgonje AR, Blokzijl T, Dijkstra G, Faber KN, et al. The role of gut microbiota in health and disease: In vitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. *Anaerobe*. 2017; 44: 3–12. <https://doi.org/10.1016/j.anaerobe.2017.01.001> PMID: 28062270
7. Harmsen HJ, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn's disease patients have more IgG-binding fecal bacteria than controls. *Clin Vaccine Immunol*. 2012; 19(4): 515–521. <https://doi.org/10.1128/CVI.05517-11> PMID: 22336288
8. Antoni L, Nuding S, Wehkamp J, Stange EF. Intestinal barrier in inflammatory bowel disease. *World J Gastroenterol*. 2014; 20(5): 1165–1179. <https://doi.org/10.3748/wjg.v20.i5.1165> PMID: 24574793
9. Teshima CW, Dieleman LA, Meddings JB. Abnormal intestinal permeability in Crohn's disease pathogenesis. *Ann N Y Acad Sci*. 2012; 1258: 159–165. <https://doi.org/10.1111/j.1749-6632.2012.06612.x> PMID: 22731729
10. Ahmad R, Sorrell MF, Batra SK, Dhawan P, Singh AB. Gut permeability and mucosal inflammation: bad, good or context dependent. *Mucosal Immunol*. 2017; 10(2): 307–317. <https://doi.org/10.1038/mi.2016.128> PMID: 28120842
11. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. *Gastroenterology*. 2000; 119(6): 1740–1744. PMID: 11113095
12. Jørgensen J, Ranløv PJ, Bjerrum PJ, Diemer H, Bisgaard K, Elsborg L. Is an increased intestinal permeability a valid predictor of relapse in Crohn disease? *Scand J Gastroenterol*. 2001; 36(5): 521–527. PMID: 11346207
13. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. *Lancet*. 1993; 341(8858): 1437–1439. PMID: 8099141
14. D'Incà R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. *Am J Gastroenterol*. 1999; 94(10): 2956–2960. <https://doi.org/10.1111/j.1572-0241.1999.01444.x> PMID: 10520851
15. Secondulfo M, de Magistris L, Fiandra R, Caserta L, Belletta M, Tartaglione MT, et al. Intestinal permeability in Crohn's disease patients and their first degree relatives. *Dig Liver Dis*. 2001; 33(8): 680–685. PMID: 11785714
16. Söderholm JD, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? *Gut*. 1999; 44(1): 96–100. PMID: 9862833
17. Bourgonje AR, von Martels JZH, de Vos P, Faber KN, Dijkstra G. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines. *PLoS One*. 2018; 13(2): e0193202. <https://doi.org/10.1371/journal.pone.0193202> PMID: 29466406
18. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. *Inflamm Bowel Dis*. 2008; 14(1): 40–46. <https://doi.org/10.1002/ibd.20312> PMID: 18022866

19. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. *Gut*. 2000; 47(4): 506–513. <https://doi.org/10.1136/gut.47.4.506> PMID: 10986210
20. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. *Am J Gastroenterol*. 2008; 103(1): 162–169. <https://doi.org/10.1111/j.1572-0241.2007.01556.x> PMID: 17916108
21. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. *Therap Adv Gastroenterol*. 2015; 8(1): 23–36. <https://doi.org/10.1177/1756283X14553384> PMID: 25553077
22. Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. *Gastroenterology*. 2015; 149(5): 1275–1285.e2. <https://doi.org/10.1053/j.gastro.2015.07.003> PMID: 26166315
23. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. *Scand J Gastroenterol*. 2000; 35(11): 1163–1169. PMID: 11145287
24. Andre F, Andre C, Emery Y, Forchon J, Descos L, Minaire Y. Assessment of the lactulose-mannitol test in Crohn's disease. *Gut*. 1988; 29(4): 511–515. PMID: 3131194
25. Ainsworth M, Eriksen J, Rasmussen JW, Schaffalitzky de Muckadell, OB. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. *Scand J Gastroenterol*. 1989; 24(8): 993–998. PMID: 2512633
26. Arslan G, Atasever T, Cindoruk M, Yildirim IS. (51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis. *Nucl Med Commun*. 2001; 22(9): 997–1001. PMID: 11505209
27. Bjarnason I, O'Morain C, Levi AJ, Peters TJ. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. *Gastroenterology*. 1983; 85(2): 318–322. PMID: 6407889
28. Jenkins AP, Nukajam WS, Menzies IS, Creamer B. Simultaneous administration of lactulose and 51Cr-ethylenediaminetetraacetic acid. A test to distinguish colonic from small-intestinal permeability change. *Scand J Gastroenterol*. 1992; 27(9): 769–773. PMID: 1411284
29. Jenkins RT, Ramage JK, Jones DB, Collins SM, Goodacre RL, Hunt RH. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. *Clin Invest Med*. 1988; 11(2): 151–155. PMID: 3135136
30. O'Morain CA, Abelow AC, Chervu LR, Fleischner GM, Das KM. Chromium 51-ethylenediaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease. *J Lab Clin Med*. 1986; 108(5): 430–435. PMID: 3095471
31. Peled Y, Watz C, Gilat T. Measurement of intestinal permeability using 51Cr-EDTA. *Am J Gastroenterol*. 1985; 80(10): 770–773. PMID: 3929593
32. Pironi L, Miglioli M, Ruggeri E, Levorato M, Dallasta MA, Corbelli C, et al. Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease. *Dig Dis Sci*. 1990; 35(5): 582–588. PMID: 1691967
33. Turck D, Ythier H, Maquet E, Deveaux M, Marchandise X, Farriaux JP, et al. Intestinal permeability to [51Cr]EDTA in children with Crohn's disease and celiac disease. *J Pediatr Gastroenterol Nutr*. 1987; 6(4): 535–537. PMID: 3123634
34. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Van der Meer R. Dietary fructooligosaccharides increase intestinal permeability in rats. *J Nutr*. 2005; 135(4): 837–842. <https://doi.org/10.1093/jn/135.4.837> PMID: 15795444
35. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Katan MB, van der Meer R. Dietary fructooligosaccharides affect intestinal barrier function in healthy men. *J Nutr*. 2006; 136(1): 70–74. <https://doi.org/10.1093/jn/136.1.70> PMID: 16365061
36. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. *Gut*. 2000; 47(4): 527–532. <https://doi.org/10.1136/gut.47.4.527> PMID: 10986213
37. Andersen R, Laerum F. Intestinal permeability measurements—a new application for water soluble contrast media? *Acta Radiol Suppl*. 1995; 399: 247–252. PMID: 8610523
38. Bjarnason I, Maxton D, Reynolds AP, Catt S, Peters TJ, Menzies IS. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. *Scand J Gastroenterol*. 1994; 29(7): 630–639. PMID: 7939400
39. Oman H, Blomquist L, Henriksson AE, Johansson SG. Comparison of polysucrose 15000, 51Cr-labelled ethylenediaminetetraacetic acid, and 14C-mannitol as markers of intestinal permeability in man. *Scand J Gastroenterol*. 1995; 30(12): 1172–1177. PMID: 9053970

40. Aabakken L. Cr-ethylenediaminetetraacetic acid absorption test. Methodologic aspects. *Scand J Gastroenterol.* 1989; 24(3): 351–358. PMID: [2499921](#)
41. Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS. Lactulose, ⁵¹Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. *Clin Sci (Lond).* 1986; 71(1): 71–80. PMID: [3086024](#)
42. Binnerts W, Van 'T Klooster AT, Frens AM. Soluble Chromium indicator measured by atomic absorption in digestion experiments. *Veterinary Record.* 1968; 82: 470.
43. Goullé J, Mahieu L, Castermant J, Neveu N, Bonneau L, Lainé G, et al. Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair. *Forensic Sci Int.* 2005; 153(1): 39–44. <https://doi.org/10.1016/j.forsciint.2005.04.020> PMID: [15979835](#)
44. Harmsen HJM, Raangs GC, He T, Degener JE, Welling GW. Extensive Set of 16S rRNA-Based Probes for Detection of Bacteria in Human Feces. *Appl Environ Microbiol.* 2002; 68(6): 2982–2990. <https://doi.org/10.1128/AEM.68.6.2982-2990.2002> PMID: [12039758](#)
45. Suau A, Rochet V, Sghir A, Gramet G, Brewaeys S, Sutren M, et al. *Fusobacterium prausnitzii* and Related Species Represent a Dominant Group Within the Human Fecal Flora. *Syst Appl Microbiol.* 2001; 24(1): 139–145.
46. Amann RI, Binder BJ, Olson RJ, Chisholm SW, Devereux R, Stahl DA. Combination of 16S rRNA-Targeted Oligonucleotide Probes with Flow Cytometry for Analyzing Mixed Microbial Populations. *Appl Environ Microbiol.* 1990; 56(6): 1919–1925. PMID: [2200342](#)
47. Poulsen LK, Lan F, Kristensen CS, Hobolth P, Molin S, Krogfelt KA. Spatial distribution of *Escherichia coli* in the mouse large intestine inferred from rRNA in situ hybridization. *Infect Immun.* 1994; 62(11): 5191–5194. PMID: [7927805](#)
48. [Anonymous]. <http://www.inchem.org/documents/ehc/ehc/ehc61.htm>.
49. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. *J Immunol Methods.* 2015; 421: 44–53. <https://doi.org/10.1016/j.jim.2014.12.015> PMID: [25595554](#)
50. Scaioi E, Cardamone C, Scagliarini M, Zagari RM, Bazzoli F, Belluzzi A. Can fecal calprotectin better stratify Crohn's disease activity index? *Ann Gastroenterol.* 2015; 28(2): 247–252. PMID: [25831217](#)
51. Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. *Gut.* 2013; 62(12): 1806–1816. <https://doi.org/10.1136/gutjnl-2012-303957> PMID: [24203056](#)
52. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. *Clin Gastroenterol Hepatol.* 2008; 6(11): 1218–1224. <https://doi.org/10.1016/j.cgh.2008.06.010> PMID: [18799360](#)
53. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. *Scand J Gastroenterol.* 2000; 35(1): 64–69. PMID: [10672837](#)
54. Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. *Inflamm Bowel Dis.* 2005; 11(7): 667–673. PMID: [15973122](#)
55. Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, et al. The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation. *Nutrients.* 2018; 10(8): pii: E988. <https://doi.org/10.3390/nu10080988> PMID: [30060606](#)
56. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. *Gastroenterology.* 1989; 97(4): 927–931. PMID: [2506103](#)
57. Takeuchi K, Maiden L, Bjarnason I. Genetic aspects of intestinal permeability in inflammatory bowel disease. *Novartis Found Symp.* 2004; 263: 151–158. PMID: [15669640](#)
58. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. *Ann Intern Med.* 1986; 105(6): 883–885. PMID: [3777713](#)
59. Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, et al. Sub-clinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? *Gastroenterology.* 2003; 124(7): 1728–1737. PMID: [12806605](#)
60. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology.* 2014; 146(6): 1489–1499. <https://doi.org/10.1053/j.gastro.2014.02.009> PMID: [24560869](#)
61. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. *Gut.* 2003; 52(2): 237–242. PMID: [12524406](#)